{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:39:49Z","timestamp":1791866389785,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jchf.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T18:41:07Z","timestamp":1660156867000},"page":"699-713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Angiotensinogen"],"prefix":"10.1016","volume":"10","author":[{"given":"Tanvir","family":"Kahlon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Carlisle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Otero Mostacero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Trainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"DeFilippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib1","first-page":"I4","article-title":"Circulating versus local renin-angiotensin system in cardiovascular homeostasis","volume":"77","author":"Dzau","year":"1988","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib2","article-title":"Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Sharma","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"9386","key":"10.1016\/j.jchf.2022.06.005_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jchf.2022.06.005_bib4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/hy0202.103441","article-title":"Angiotensinogen and its cleaved derivatives inhibit angiogenesis","volume":"39","author":"C\u00e9l\u00e9rier","year":"2002","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.jchf.2022.06.005_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/hr.2016.17","article-title":"Structure and functions of angiotensinogen","volume":"39","author":"Lu","year":"2016","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/ATVBAHA.115.306740","article-title":"Angiotensinogen exerts effects independent of angiotensin II","volume":"36","author":"Lu","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jchf.2022.06.005_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0092-8674(92)90275-H","article-title":"Molecular basis of human hypertension: role of angiotensinogen","volume":"71","author":"Jeunemaitre","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.jchf.2022.06.005_bib9","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(95)90115-9","article-title":"Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease","volume":"345","author":"Katsuya","year":"1995","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.HYP.0000072334.34433.17","article-title":"Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease","volume":"41","author":"Sethi","year":"2003","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.jchf.2022.06.005_bib11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1681\/ASN.2014040408","article-title":"Urinary angiotensinogen level predicts AKI in acute decompensated heart failure: a prospective, two-stage study","volume":"26","author":"Yang","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib13","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib14","first-page":"485","article-title":"Antisense inhibition of angiotensinogen with IONIS-AGT-LRx: results of phase 1 and phase 2 studies","volume":"6","author":"Morgan","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"issue":"suppl 3","key":"10.1016\/j.jchf.2022.06.005_bib15","article-title":"Abstract 14387: dose-related reductions in blood pressure with a RNA interference (RNAi) therapeutic targeting angiotensinogen in hypertensive patients: interim results from a first-in-human phase 1 study of ALN-AGT01","volume":"142","author":"Huang","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib16","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1161\/HYPERTENSIONAHA.120.16870","article-title":"CRISPR\/Cas9 mediated deletion of the angiotensinogen gene reduces hypertension: a potential for cure?","volume":"77","author":"Sun","year":"2021","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib17","first-page":"662","article-title":"Molecular genetics of human hypertension: angiotensinogen","volume":"15","author":"Corvol","year":"1997","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced EF","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0014-5793(98)01145-4","article-title":"Angiotensinogen cleavage by renin: Importance of a structurally constrained N-terminus","volume":"436","author":"Streatfeild-James","year":"1998","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.HYP.4.2.185","article-title":"Role of angiotensinogen in blood pressure homeostasis","volume":"4","author":"Gardes","year":"1982","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.HYP.1.3.287","article-title":"Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects","volume":"1","author":"Gordon","year":"1979","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-9343(91)90501-N","article-title":"Low angiotensinogen levels are related to the severity and liver dysfunction of congestive heart failure: implications for renin measurements","volume":"90","author":"Arnal","year":"1991","journal-title":"Am J Med"},{"issue":"3 II","key":"10.1016\/j.jchf.2022.06.005_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/01.HYP.27.3.465","article-title":"Mechanisms for inducible control of angiotensinogen gene transcription","volume":"27","author":"Brasier","year":"1996","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/01.RES.52.3.328","article-title":"The feedback regulation of angiotensinogen production by components of the renin-angiotensin system","volume":"52","author":"Herrmann","year":"1983","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/cvr\/27.5.731","article-title":"Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat","volume":"27","author":"Schunkert","year":"1993","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10.1016\/j.jchf.2022.06.005_bib26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.HYP.8.7.560","article-title":"Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats","volume":"8","author":"Okamura","year":"1986","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib27","first-page":"E129","article-title":"Influence of converting-enzyme inhibition on rat des-angiotensin I-angiotensinogen","volume":"246","author":"Clauser","year":"1984","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib28","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/01.HYP.19.5.456","article-title":"Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats","volume":"19","author":"Chen","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2022.06.005_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00004872-199204000-00007","article-title":"Regulation of angiotensinogen gene expression by estrogen","author":"Gordon","year":"1992","journal-title":"J\u00a0Hypertens"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-58930-7","article-title":"A\u00a0pilot study of alterations in oxidized angiotensinogen and antioxidants in pre-eclamptic pregnancy","volume":"10","author":"Dahabiyeh","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib31","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1172\/JCI99417","article-title":"RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models","volume":"130","author":"Haase","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.HYP.0000154361.47683.d3","article-title":"Weight loss and the renin-angiotensin-aldosterone system","volume":"45","author":"Engeli","year":"2005","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00004872-199816050-00003","article-title":"Angiotensinogen levels and obesity in four black populations","volume":"16","author":"Cooper","year":"1998","journal-title":"J\u00a0Hypertens"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib34","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1172\/JCI115133","article-title":"Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall","volume":"87","author":"Naftilan","year":"1991","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1161\/01.CIR.87.1.283","article-title":"Vascular injury induces angiotensinogen gene expression in the media and neointima","volume":"87","author":"Rakugi","year":"1993","journal-title":"Circulation"},{"issue":"Suppl 3A","key":"10.1016\/j.jchf.2022.06.005_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0002-9343(88)90201-X","article-title":"Cardiac renin-angiotensin system. Molecular and functional aspects","volume":"84","author":"Dzau","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2022.06.005_bib37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archinte.1993.00410080011002","article-title":"Tissue renin-angiotensin system in myocardial hypertrophy and failure","volume":"153","author":"Dzau","year":"1993","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib38","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.RES.67.3.564","article-title":"Cardiac angiotensinogen and its local activation in the isolated perfused beating heart","volume":"67","author":"Lindpaintner","year":"1990","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib39","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1161\/HYPERTENSIONAHA.112.192690","article-title":"Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice","volume":"60","author":"Yiannikouris","year":"2012","journal-title":"Hypertension"},{"issue":"2 II","key":"10.1016\/j.jchf.2022.06.005_bib40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.HYP.37.2.408","article-title":"Alterations in blood pressure and heart rate variability in transgenic rats with low brain angiotensinogen","volume":"37","author":"Baltatu","year":"2001","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/01.RES.0000120864.21172.5A","article-title":"Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen","volume":"94","author":"Wang","year":"2004","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0008-6363(99)00145-5","article-title":"The renin-angiotensin system and experimental heart failure","volume":"43","author":"Wollert","year":"1999","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib43","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1172\/JCI116020","article-title":"Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure","volume":"90","author":"Schunkert","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jchf.2022.06.005_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/jmcc.1993.1017","article-title":"Selective activation of cardiac ATG gene expression in post-infarction ventricular remodeling in the rat","volume":"25","author":"Lindpaintner","year":"1993","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1291\/hypres.19.179","article-title":"Induction of cardiac angiotensinogen mRNA and angiotensin converting enzyme (ACE) activity in isoproterenol-induced heart injury","volume":"19","author":"Ogiku","year":"1996","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib46","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.RES.66.4.883","article-title":"Angiotensin II-forming pathways in normal and failing human hearts","volume":"66","author":"Urata","year":"1990","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib47","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI116325","article-title":"Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart","volume":"91","author":"Urata","year":"1993","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib48","doi-asserted-by":"crossref","first-page":"59A","DOI":"10.1016\/0002-9149(87)90178-0","article-title":"Implications of local angiotensin production in cardiovascular physiology and pharmacology","volume":"59","author":"Dzau","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2022.06.005_bib49","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1161\/01.CIR.90.3.1328","article-title":"Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats","author":"Heymes","year":"1994","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/CIRCRESAHA.117.310978","article-title":"Multifunctional role of chymase in acute and chronic tissue injury and remodeling","volume":"122","author":"Dell\u2019italia","year":"2018","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib51","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI39345","article-title":"Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents","volume":"120","author":"Wei","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0167-4838(87)90226-3","article-title":"Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates","volume":"913","author":"Cumin","year":"1987","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"10.1016\/j.jchf.2022.06.005_bib53","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1681\/ASN.V1071598","article-title":"Gene targeting approaches to analyzing hypertension","volume":"10","author":"Takahashi","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.HYP.0000227932.13687.60","article-title":"Genetic basis of hypertension: revisiting angiotensinogen","volume":"48","author":"Dickson","year":"2006","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib55","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1086\/515452","article-title":"Haplotypes of angiotensinogen in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.jchf.2022.06.005_bib56","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/01.ATV.0000079007.40884.5C","article-title":"Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis","volume":"23","author":"Sethi","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jchf.2022.06.005_bib57","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1172\/JCI117083","article-title":"Angiotensinogen as a risk factor for essential hypertension in Japan","volume":"93","author":"Hata","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jchf.2022.06.005_bib58","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1161\/01.HYP.33.6.1324","article-title":"Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel","author":"Corvol","year":"1999","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib59","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"2\u20133","key":"10.1016\/j.jchf.2022.06.005_bib60","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0167-5273(02)00506-5","article-title":"Association of two angiotensinogen gene polymorphisms, M235T and G(-6)A, with chronic heart failure","volume":"89","author":"Goldbergova","year":"2003","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib61","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/01.HYP.0000253061.30170.68","article-title":"Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure","volume":"49","author":"Pilbrow","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib62","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.4238\/2015.April.22.5","article-title":"T174M polymorphism in the angiotensinogen gene and risk of myocardial infarction: a meta-analysis","volume":"14","author":"Hu","year":"2015","journal-title":"Genet Mol Res"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.33549\/physiolres.931976","article-title":"Difference in angiotensinogen haplotype frequencies between chronic heart failure and advanced atherosclerosis patients - new prognostic factor?","volume":"60","author":"Goldbergov\u00e1","year":"2011","journal-title":"Physiol Res"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib64","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/01.HYP.37.3.875","article-title":"Angiotensinogen polymorphisms and elevated blood pressure in the general population: the Copenhagen City Heart Study","volume":"37","author":"Sethi","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2022.06.005_bib65","article-title":"The genes polymorphism of angiotensinogen (AGT) M235T and AGT T174M in patients with essential hypertension: a meta-analysis","volume":"16","author":"Fajar","year":"2019","journal-title":"Gene Rep"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib66","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1161\/01.HYP.30.6.1331","article-title":"Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal","volume":"30","author":"Kunz","year":"1997","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib67","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1161\/01.HYP.31.5.1166","article-title":"Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats","volume":"31","author":"Makino","year":"1998","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BSR20180201","article-title":"Antisense oligonucleotides targeting angiotensinogen: Insights from animal studies","volume":"39","author":"Wu","year":"2019","journal-title":"Biosci Rep"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib69","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1753944716642677","article-title":"Cardiac remodelling and RAS inhibition","volume":"10","author":"Ferrario","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"8","key":"10.1016\/j.jchf.2022.06.005_bib70","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1\u20137 axis of the renin\u2013angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib71","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0735-1097(99)00199-0","article-title":"Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes","volume":"34","author":"Karjalainen","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib72","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ajh\/hpx156","article-title":"Systemic angiotensinogen concentrations are independently associated with left ventricular diastolic function in a community sample","volume":"31","author":"Millen","year":"2018","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib73","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00004872-200204000-00023","volume":"20","author":"Kurland","year":"2002","journal-title":"J\u00a0Hypertens"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib74","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.2003.00933.x","article-title":"Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients","volume":"63","author":"Wang","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib75","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1067\/mhj.2002.121926","article-title":"Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study","volume":"143","author":"Tang","year":"2002","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/01.HYP.29.1.165","article-title":"Angiotensin-converting enzyme and angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions. A twin study","volume":"29","author":"Busjahn","year":"1997","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib77","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2125.2007.03091.x","article-title":"Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure","volume":"65","author":"Zakrzewski-Jakubiak","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib78","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/1470320312465455","article-title":"The M235T polymorphism in the angiotensinogen gene and heart failure: a meta-analysis","volume":"15","author":"Chen","year":"2014","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"10.1016\/j.jchf.2022.06.005_bib79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1523-1755.2002.00155.x","article-title":"Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production","volume":"61","author":"Kobori","year":"2002","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib80","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1681\/ASN.2006060554","article-title":"Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease","volume":"18","author":"Yamamoto","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.jchf.2022.06.005_bib81","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"11","key":"10.1016\/j.jchf.2022.06.005_bib82","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/hr.2017.65","article-title":"Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?","volume":"40","author":"Nehme","year":"2017","journal-title":"Hypertens Res"},{"issue":"9638","key":"10.1016\/j.jchf.2022.06.005_bib83","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jchf.2022.06.005_bib84","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jchf.2022.06.005_bib85","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","volume":"14","author":"Lakhdar","year":"2008","journal-title":"J\u00a0Card Fail"},{"issue":"11","key":"10.1016\/j.jchf.2022.06.005_bib87","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib88","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2459\/JCM.0000000000000156","article-title":"Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism","volume":"16","author":"Vergaro","year":"2015","journal-title":"J\u00a0Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib89","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ihj.2012.06.015","article-title":"ALTITUDE halted: adverse events when aliskiren added to ACEI, ARB therapy","volume":"64","author":"Guha","year":"2012","journal-title":"Indian Heart J"},{"issue":"16","key":"10.1016\/j.jchf.2022.06.005_bib90","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.jchf.2022.06.005_bib91","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jchf.2022.06.005_bib92","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.113.02893","article-title":"Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition","volume":"63","author":"Balcarek","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"issue":"2 II","key":"10.1016\/j.jchf.2022.06.005_bib94","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.HYP.37.2.376","article-title":"Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense","volume":"37","author":"Kimura","year":"2001","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib95","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1101\/pdb.top097436","article-title":"RNA interference and small RNA analysis","volume":"2019","author":"Li","year":"2019","journal-title":"Cold Spring Harb Protoc"},{"issue":"3","key":"10.1016\/j.jchf.2022.06.005_bib96","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0008-6363(99)00254-0","article-title":"Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats","volume":"44","author":"Makino","year":"1999","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.jchf.2022.06.005_bib97","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.100.9.899","article-title":"Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein","volume":"100","author":"Morawietz","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib98","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/j.1476-5381.2011.01712.x","article-title":"Comparative effects of different modes of renin\u00a0angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis","volume":"165","author":"Lu","year":"2012","journal-title":"Br\u00a0J Phrmacol"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib99","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/FPC.0b013e3282fce3bd","article-title":"Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population","volume":"18","author":"Ravn","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib100","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000057403","article-title":"Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy","volume":"24","author":"Flack","year":"1998","journal-title":"Miner Electrolyte Metab"},{"issue":"8","key":"10.1016\/j.jchf.2022.06.005_bib101","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.jhh.1002198","article-title":"Polymorphisms of angiotensinogen and angiotensin-converting enzyme associated with lower extremity arterial disease in the Health, Aging and Body Composition study","volume":"21","author":"Li","year":"2007","journal-title":"J\u00a0Hum Hypertens"},{"issue":"1","key":"10.1016\/j.jchf.2022.06.005_bib102","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3892\/etm.2012.790","article-title":"Assessment of two missense polymorphisms (rs4762 and rs699) of the angiotensinogen gene and stroke","volume":"5","author":"Park","year":"2013","journal-title":"Exp Ther Med"},{"issue":"4","key":"10.1016\/j.jchf.2022.06.005_bib103","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1470320311399605","article-title":"Polymorphisms of the angiotensin-converting enzyme and angiotensinogen gene in patients with atrial fibrillation","volume":"12","author":"Topal","year":"2011","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"13","key":"10.1016\/j.jchf.2022.06.005_bib104","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.CIR.0000124487.36586.26","article-title":"Renin-angiotensin system gene polymorphisms and atrial fibrillation","volume":"109","author":"Tsai","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2022.06.005_bib105","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0735-1097(01)01186-X","article-title":"Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study","volume":"37","author":"Rodr\u00edguez-P\u00e9rez","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1-3","key":"10.1016\/j.jchf.2022.06.005_bib106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2005.10.062","article-title":"Effects of losartan and irbesartan administration on brain angiotensinogen mRNA levels","volume":"528","author":"Pediconi","year":"2005","journal-title":"Eur J Pharmacol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922004000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922004000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:00:47Z","timestamp":1761973247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177922004000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":106,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2213177922004000"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2022.06.005","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensinogen","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}